Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects
Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved..
In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19. Fifteen patients with a history of lymphoma, CLL, and MM were included. Eight were male, median age was 74. All patients had an immediate clinical and virological response. In 73 % of patients, PCR for SARS-CoV-2 became negative at the end of treatment and the rest had an increase in PCR cycle threshold (CT) values, with a median increase of 6 cycles. After a follow-up of three months, 60 % of patients remained in full clinical and virological remission. None required invasive mechanical ventilation or died. The side effects we observed, neutropenia, lactatemia and elevated transaminases, were mild and almost all transient in nature. We conclude that dual anti-viral treatment appears to be a valid treatment option for persistent COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 30(2024), 3 vom: 22. Feb., Seite 271-275 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meijer, Suzy E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jiac.2023.10.022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364364106 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364364106 | ||
| 003 | DE-627 | ||
| 005 | 20240214232915.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jiac.2023.10.022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM364364106 | ||
| 035 | |a (NLM)37944697 | ||
| 035 | |a (PII)S1341-321X(23)00267-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meijer, Suzy E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19. Fifteen patients with a history of lymphoma, CLL, and MM were included. Eight were male, median age was 74. All patients had an immediate clinical and virological response. In 73 % of patients, PCR for SARS-CoV-2 became negative at the end of treatment and the rest had an increase in PCR cycle threshold (CT) values, with a median increase of 6 cycles. After a follow-up of three months, 60 % of patients remained in full clinical and virological remission. None required invasive mechanical ventilation or died. The side effects we observed, neutropenia, lactatemia and elevated transaminases, were mild and almost all transient in nature. We conclude that dual anti-viral treatment appears to be a valid treatment option for persistent COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dual anti-viral therapy | |
| 650 | 4 | |a Hemato-oncological patients | |
| 650 | 4 | |a Immunocompromised patients | |
| 650 | 4 | |a Persistent COVID-19 | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Halutz, Ora |e verfasserin |4 aut | |
| 700 | 1 | |a Adler, Amos |e verfasserin |4 aut | |
| 700 | 1 | |a Levytskyi, Katya |e verfasserin |4 aut | |
| 700 | 1 | |a Tau, Luba |e verfasserin |4 aut | |
| 700 | 1 | |a Dekel, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Poradosu, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Katchman, Evgene |e verfasserin |4 aut | |
| 700 | 1 | |a Shasha, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ablin, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Choshen, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Giris |e verfasserin |4 aut | |
| 700 | 1 | |a Wasserman, Asaf |e verfasserin |4 aut | |
| 700 | 1 | |a Ingbir, Merav |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Yael C |e verfasserin |4 aut | |
| 700 | 1 | |a Perry, Chava |e verfasserin |4 aut | |
| 700 | 1 | |a Ram, Ron |e verfasserin |4 aut | |
| 700 | 1 | |a Herishanu, Yair |e verfasserin |4 aut | |
| 700 | 1 | |a Bar On, Yael |e verfasserin |4 aut | |
| 700 | 1 | |a van Thijn, Elma |e verfasserin |4 aut | |
| 700 | 1 | |a Rutsinsky, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Harari, Sheri |e verfasserin |4 aut | |
| 700 | 1 | |a Stern, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Ami, Ronen |e verfasserin |4 aut | |
| 700 | 1 | |a Paran, Yael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |d 1996 |g 30(2024), 3 vom: 22. Feb., Seite 271-275 |w (DE-627)NLM095488073 |x 1437-7780 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:3 |g day:22 |g month:02 |g pages:271-275 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jiac.2023.10.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 3 |b 22 |c 02 |h 271-275 | ||